Evidence map›Paper›PMID 41079559›Full record

ArticleBiologics : targets & therapy2025

The Potential of Telitacicept in Treating Lupus erythematosus panniculitis: A Case Report.

Xinying Xie, Shuibo Tang, Ma Huang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biologics : targets & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinying Xie *Rheumatology and Immunology Department, Hunan University of Medicine General Hospital, Huaihua, Hunan, People's Republic of China.
Shuibo Tang *Rheumatology and Immunology Department, Hunan University of Medicine General Hospital, Huaihua, Hunan, People's Republic of China.
Ma HuangDepartment of Intensive Care Medicine, Hunan University of Medicine General Hospital, Huaihua, Hunan, People's Republic of China.ORCID 0009-0000-6769-2986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus erythematosus panniculitis (LEP) is a rare and serious skin lesion associated with systemic lupus erythematosus (SLE). In the past, the management of LEP has followed the treatment guidelines for SLE, which is based on the administration of high doses of hormones together with immunosuppressants, with no treatment plans specific for LEP. However, the long-term use of high hormone doses and immunosuppressants can exacerbate skin breakage and calcification. Telitacicep is an approved biological agent demonstrating significant therapeutic efficacy in immune system disorders. We report a case of lupus erythematosus panniculitis in which the patient's clinical symptoms and laboratory test results improved after treatment with a combination of steroids, cyclophosphamide, and the biologic agent Telitacicept. The condition was significantly controlled and alleviated. This report highlights the successful application of Telitacicept in the treatment of lupus panniculitis, providing valuable insights for future management of this condition.

Indexed as

biologicalsLupus erythematosus panniculitisTelitacicept

Identifiers

PMID41079559
PMCPMC12515005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.